ARG
Neuromuscular Disease Caused By Qualitative Or Quantitative Defects Of Dystrophin
Massachusetts General HospitalSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Neuromuscular Disease Caused By Qualitative Or Quantitative Defects Of Dystrophin cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zeleciment Rostudirsen Dyne Therapeutics | Phase 3 | B |
Ataluren PTC Therapeutics | Phase 3 | B |
Givinostat Italfarmaco | Phase 1 | CC |
Moxifloxacin Italfarmaco | Phase 1 | CC |
Same molecule, other indications
ARG is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →